NewAmsterdam, which reported another phase 3 win in July, plans to use the data to file for approval. However, as happened in ...

Learn about typical dosages of atorvastatin oral tablet for high cholesterol and heart-related risks, including what’s ...

Dutch biotech NewAmsterdam Pharma (NASDAQ:NAMS) announced Wednesday that its oral anti-cholesterol therapy containing ...

Long-term use of cardiovascular drugs may reduce dementia risk in older adults by up to 25%, while antiplatelet drugs could ...

Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) ...

Altered sphingolipid biosynthetic flux and lipoprotein trafficking contribute to trans fat-induced atherosclerosis - (https:/ ...

The cholesterol-lowering drug has been classed as a breakthrough therapy for homozygous familial hypercholesterolaemia (HoFH) by the FDA, which is due to deliver a decision on the marketing ...

Researchers have found that long-term use of drugs for hypertension and high cholesterol also lowers the risk of developing ...

People born with inherited high cholesterol — known as the “evil cousin” — may soon have access to new and potentially ...

AstraZeneca has bought rights to an orally-active drug that inhibits PCSK9, offering a patient-friendly alternative to current cholesterol-lowering therapies that have to be delivered via a needle.

Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns ...

Eli Lilly's muvalaplin Phase 2 trial showed significant Lp(a) reduction, meeting primary and secondary endpoints with ...